For academics in resource-constrained countries like Thailand, the motivation to launch a company isn't just commercial. It's a response to the 'impact gap,' where publicly-funded research ends in publications without creating tangible value, jobs, or solutions for the nation.
In resource-constrained environments, perfect conditions for starting a company never exist. Professor Waranyoo Phoolcharoen advises entrepreneurs to embrace feeling unready, as waiting for certainty means you will never start. Courage is not the absence of fear, but moving forward despite it.
The belief that bioprocess development must take a long time becomes a self-fulfilling prophecy. Professor Waranyoo Phoolcharoen argues that integrating manufacturing, scalability, and downstream constraints from day one can significantly shorten timelines, challenging the industry's traditional, sluggish mindset.
BioPhytopharm, aiming to make vaccines, first commercialized cosmetic ingredients. This strategy provides early revenue and market validation with lower regulatory hurdles, a crucial de-risking step for deep tech startups, especially in capital-scarce emerging markets.
The biotech landscape in Southeast Asia has strong scientific talent but lacks a mature 'translation ecosystem' (VCs, experienced operators). Founders must take on the dual role of building their company and simultaneously cultivating the surrounding infrastructure, including talent, partnerships, and public trust.
A critical step for technical founders is honestly assessing their non-scientific weaknesses. Professor Waranyoo Phoolcharoen knew she couldn't be both CTO and CEO, so she deliberately sought a co-founder with strong business, finance, and marketing skills to complement her technical expertise.